BANDERA, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 2.969
EU - Europa 1.596
AS - Asia 903
SA - Sud America 55
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 5.543
Nazione #
US - Stati Uniti d'America 2.879
SG - Singapore 382
CN - Cina 264
IE - Irlanda 258
RU - Federazione Russa 249
IT - Italia 244
DE - Germania 238
SE - Svezia 230
HK - Hong Kong 129
UA - Ucraina 101
CA - Canada 75
GB - Regno Unito 74
DK - Danimarca 54
BR - Brasile 49
FI - Finlandia 48
ID - Indonesia 24
VN - Vietnam 24
AT - Austria 21
TR - Turchia 20
IN - India 19
NL - Olanda 18
FR - Francia 14
BE - Belgio 13
PL - Polonia 10
IR - Iran 7
EU - Europa 5
HN - Honduras 5
JP - Giappone 5
AU - Australia 4
BZ - Belize 4
CZ - Repubblica Ceca 4
CH - Svizzera 3
CR - Costa Rica 3
EG - Egitto 3
IL - Israele 3
KR - Corea 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
AR - Argentina 2
AZ - Azerbaigian 2
BD - Bangladesh 2
ES - Italia 2
IQ - Iraq 2
KH - Cambogia 2
LV - Lettonia 2
ML - Mali 2
MX - Messico 2
MY - Malesia 2
PT - Portogallo 2
RO - Romania 2
SA - Arabia Saudita 2
SC - Seychelles 2
UY - Uruguay 2
BG - Bulgaria 1
BS - Bahamas 1
BY - Bielorussia 1
CL - Cile 1
EE - Estonia 1
GR - Grecia 1
JO - Giordania 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MN - Mongolia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
SI - Slovenia 1
TH - Thailandia 1
Totale 5.543
Città #
Ann Arbor 375
Fairfield 276
Chandler 271
Dublin 253
Singapore 247
Woodbridge 186
Houston 185
Wilmington 169
Frankfurt am Main 159
Ashburn 143
Hong Kong 126
New York 113
Jacksonville 100
Seattle 99
Dearborn 96
Cambridge 94
Milan 77
Princeton 71
Santa Clara 59
Shanghai 46
Nanjing 41
Los Angeles 36
Lawrence 32
Altamura 31
Ottawa 28
Helsinki 26
Beijing 21
Fremont 21
Florence 19
Lachine 19
Nanchang 19
San Diego 19
Dong Ket 18
Jakarta 18
Buffalo 14
Brussels 13
Andover 12
Edmonton 12
London 12
Shenyang 12
Vienna 12
Munich 11
Nuremberg 11
Guangzhou 10
Hebei 10
Moscow 10
Kunming 9
Toronto 9
Boardman 8
Hangzhou 8
Kiev 8
Amsterdam 7
Changsha 7
Falls Church 7
Jinan 7
Norwalk 7
Tianjin 7
Zhengzhou 7
Council Bluffs 6
Pune 6
Romola 6
São Paulo 6
Hanoi 5
Tegucigalpa 5
Tokyo 5
Belize City 4
Enterprise 4
Piacenza 4
Polska 4
Rio de Janeiro 4
San Francisco 4
Taizhou 4
Casper 3
Clearwater 3
Columbus 3
Coventry 3
Darlington 3
Detroit 3
Edinburgh 3
Hyderabad 3
Kilburn 3
Melzo 3
Ningbo 3
Rome 3
Semarang 3
Acton 2
Ancona 2
Aversa 2
Baku 2
Bamako 2
Berlin 2
Brno 2
Buenos Aires 2
Cairo 2
Carate Brianza 2
Chicago 2
Cotia 2
Dallas 2
Delhi 2
Düsseldorf 2
Totale 3.859
Nome #
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 245
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 238
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 224
Microbiota in ICU, not only a gut problem 223
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 218
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 212
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 198
Brachial and central blood pressure in HIV-infected subjects 192
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 190
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 186
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 184
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 183
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 182
Unmasking tuberculosis in the era of antiretroviral treatment 172
Strategies to limit immune-activation in HIV patients 172
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 170
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 170
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 169
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 168
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 152
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 151
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 149
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 142
Exogenous reinfection of tuberculosis in a low-burden area 117
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 97
Plasma proteome investigation of COVID-19 patients with different outcomes through an untargeted label-free LC-MS/MS approach. 96
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 93
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 92
Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study 86
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 83
Arterial structural and functional effects of two different antiretroviral therapy protocol on naïve HIV-infected subjects 80
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 79
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 76
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 73
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 70
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 69
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 66
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 64
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 63
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 55
Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study(Front. Med., (2022), 9, (850858), 10.3389/fmed.2022.850858) 54
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 52
Characterization of SARS-CoV-2 proteins and human proteome in COVID-19 patients’ saliva and plasma: an untargeted mass spectrometry approach 50
Plasma proteomic signatures related to COVID-19 disease severity by an untargeted nLC-ESI-MS/MS approach 47
Plasma, Intracellular and Lymph Node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 34
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 34
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 31
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 3
Totale 5.954
Categoria #
all - tutte 24.529
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.529


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020191 0 0 0 0 0 0 0 0 0 88 81 22
2020/2021510 35 48 60 48 31 49 40 55 47 37 21 39
2021/2022474 15 21 46 60 20 48 21 36 23 55 29 100
2022/2023959 102 316 74 113 40 129 10 68 65 8 23 11
2023/2024754 19 14 46 32 92 217 144 37 52 23 6 72
2024/20251.248 88 181 125 90 147 78 131 38 206 164 0 0
Totale 5.954